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Abstract 
In travel medicine efforts should be concentrated 
on preventive measures that are necessary, and 
travellers should be spared the side effects, costs and 
stress of superfluous measures. Excess mortality 
abroad is mainly due to traffic and swimming 
accidents, indicating the need for appropriate control 
strategies. The morbidity in travellers to developing 
countries is high, and is primarily due to traveller’s 
diarrhoea. As prophylaxis is ineffective or unrealistic, 
and as travellers often need fast relief, it is recom- 
mended to include loperamide and an antimicrobial 
agent in the travel kit. Recent studies have shown that 
the incidence rate per month of Plasmodium falcipar- 
urn malaria in Africa may reach 24/1000. The most 
frequently occurring immunizable diseases are hepati- 
tis A (311000) and hepatitis B (0*8/1000). For many 
tourists and some expatriates pre-travel advice 
(hygiene, measures against mosquito bites, etc.) as 
well as chemoprophylaxis and immunization can be 
limited to these infections, but those travelling or 
staying outside large centres need additional mea- 
sures. 
Origin and present importance of travel medicine 
Twenty years ago, the term travel medicine was 
unknown. However, even around 1600, young Rosa- 
lind asked the epidemiological question ‘Alas, what 
danger will it be to us, maids as we are, to travel forth 
so far!’ (As You Like It, act 1, scene 3, lines 104105). 
The need to take preventive measures was also 
known, as exemplified by the warning ‘Those girls of 
Italy, take heed of them’ (All’s Well That Ends Well, 
act 2, scene 1, line 19). For a long time medical advice 
for future travellers was based on anecdotal experi- 
ence and not on firm data. It was probably KEAN 
(1963) who initiated modern travel medicine by 
assessing health risks in travellers and measures to 
reduce them. 
The goal of travel medicine is to promote traveller’s 
health, and this goes far beyond tropical medicine and 
parasitology, as aspects of other disciplines such as 
psychiatry, high altitude pathophysiology and be- 
havioural sciences must also be considered. To 
develop rational guidelines for prevention of death 
and illness, it is necessary to balance the risks of dying 
and of morbidity against the risks, benefits and costs 
of prevention. The 20 million residents of industrial- 
ized nations who travel each year to developing 
countries (Fig. 1; IATA, 1990) especially need such 
guidelines, which should be known to practising 
physicians. I shall review the data on the risks of 
mortality and morbidity associated with travel and 
relate this information to available prevention mea- 
sures. 
Mortality data 
In American travellers, the most frequent cause of 
death abroad was cardiovascular disease (Table l), 
1970 1973 ,976 ,979 1982 1985 1988 
year 
Fig. 1. Proportion of the population in industrialized nations which 
travels to developing countries per year. 
Table 1. Fatalities among travellets abroad (percent) 
Origin US’ 
Destination Anywhere 
Number 2463 Year 197511984 
Cardiovascular 49 
Infection 1 
Other illness ? 
Swiss? 
Ey-,” 1987 
14 
-2 
Swissb 
Overseas 
1%7 
15 
; 
gggy: ; },, ‘i ji3 j I4 
Unknown :: 5: 
‘From HARGARTEN er al. (1989). 
bFrom LUSTENBERGER (1988). 
but age-specific mortality rates were similar to those 
in the population remaining in the United States. 
Fatal infections were fairly successfully prevented; 
those which most often resulted in loss of lives were 
pneumonias. In contrast, death rates due to injury 
were increased by a factor of 2-3 in lu year old 
travellers. Most fatal accidents were traflic or swim- 
ming accidents. Death statistics are incomplete, 
because no data are available on deaths which occur 
after return. 
The following advice has been proposed to reduce 
fatal injuries: avoid using motorcycles and riding on 
the back of open trucks; avoid small, non-scheduled 
aircraft; avoid travel at night; use seat belts in cars, 
and require them as a condition of rental; use helmets, 
if bicycles or motorcycles cannot be avoided; carefully 
select swimming areas; and avoid alcohol and food 
before swimming (HARGARTEN et al., 1989). 
Car rental agencies should be required to provide 
seat belts. The cooperation of the travel industry 
would be helpful. 
Morbidity data: general aspects 
Up to 78% of short-term travellers to the tropics or 
to Europe reported some health impairment (KEN- 
Fig, 2. Incidence of traveIIer’s diarrhoea per 14 days of stay in 22 645 European tourists to various destinations. 
DRICK, 1972; STEFFEN et al., 1978; PELTOLA et al., 
1983; COSSAR & REID. 1989). The majority of these 
self-reported health problems were not severe: 21- 
43% felt ill, but only 5% needed medical attention, 
and <l% had to stay in a hospital, and then usually 
for only a few days. All studies showed that traveller’s 
diarrhoea was the most frequent ailment of travellers 
to developing countries. 
Traveller’s diarrhoea (TD) 
The incidence rates per two-weeks stay vary 
between destinations (Fig. 2) (STEFFEN et al., 1983). 
Most of the data were assessed 8-10 years ago, but 
destinations in the southern and eastern Mediterra- 
nean were reassessed last in autumn 1989, and the 
rates remained virtually unchanged (BRENNER et al., 
in press). There are 3 levels of risk for TD. Travellers 
originating in industrialized countries and staying for 
2 weeks inCanada or the USA, northern and central 
Europe, Australia and New Zealand, show a low 
incidence rate, at most 8%. Intermediate incidence 
rates (8-20%) are found in most destinations of the 
Caribbean, in southern Europe, Israel, Japan and 
South Africa. In developing countries the incidence 
rates vary between 20 and 55%. 
Fig. 3. Symptoms of travebx’s diarrhoea. 
stools. 
episode starting about a week after arrival in 20% of 
the cases. Untreated, the average duration of TD is 
4 d, with 1% suffering over a month (STEFFEN & 
BOPPART, 1987). Usually traveller’s diarrhoea takes a 
mild course, but concomitant symptoms may be very 
disturbing (Fig. 3); 22% of the patients show signs of 
mucosal invasive disease with fever and/or bloody 
The incidence rates also vary depending on the 
origin of the travellets, with those living in northern 
Europe, the USA and Canada showing higher rates 
that those from southern Europe or developing 
countries (reviewed by STEFFEN & BOPPART, 1987). 
Infants and young adults show a particularly high 
incidence rate; in the former group TD is often severe 
(Pitzinger et al., paper in preparation). 
Most frequently, the symptoms of TD in tourists 
start on the third day of the stay abroad, with a second 
There are various options for prevention of TD. 
Parents with infants who intend to travel just for 
pleasure to developing countries should postpone 
their journey. Immunization may be available in the 
future (LEVINE, 1990). Travellers must be informed 
that vaccines against typhoid or cholera will not 
prevent TD. Dietary restrictions such as the rule of 
‘boil it, cook it, peel it, or forget it’ clearly reduce the 
incidence, but within the first 3 d of a stay in Kenya 
or Sri Lanka, 98% of Swiss tourists were eating 
salads, puddings, sandwiches with mixed fillings, 
using ice cubes in their drinks, or even choosing raw 
oysters or beefsteak tartare (KOTZICKI et al., 1985). It 
is not known whether travellers from other nations are 
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more disciplined. Many drugs have been proposed for 
prophylaxis of TD (Table 2), but only antimicrobial 
agents are effective. They are not indicated for every 
traveller, but may be considered for stays of less than 
2 weeks duration for travellers in whom dehydration 
and electrolyte imbalance might be particularly harm- 
ful to an underlying illness, for travellers with 
impaired immune defence, and possibly for ‘very 
important persons’ who have to eat what their hosts in 
the third world offer them. 
Because of the unsatisfactory prophylactic means 
Table 2. Efficacy and tolerance of agents used for prophylaxis and 
self-therapy of traveller’s diarrhoea’ 
DNg Efficacy Side effects 
Prophylaxis 
Lactobacilli 
Difenoxin 
Bismuth s’sal. 
TMP/SMXb 
Streptotriad 
Doxycycline 
Mecillinam 
Erythromycin 
Norl3oxacin 
Self-therapy 
Charcoal 
Lactobacilli 
ORS’ 
Loperamide 
Bismuth s’sal 
TMP/SMXb 
Doxycycline 
Fleroxacine 
Loperamide+ 
TMP/SMXb 
NOIlC 
Negative Constipation 
40-70% Few constipation, nausea 
80% Allergy 
30-60% Few allergies 
75% Photosensitivity, diarrhoea 
75% None recorded 
loo%? Allergy 
88-93% Not significant 
4h 48 h 
None None - 
None None - 
++ Initially more diarrhwa 
41% 77% More diarrhoea in dysentery 
19% 76% Black stools, black tongue 
22% 82% Allergy 
12% 87% Allergy, photosensitivity 
15% 60% Allergy 
65% 85% Allergy 
‘Sources: ERICSSON er al. (1990); STEFFEN et al. (1988); SCOTI et al. 
(1990). 
against TD, self-therapy abroad is important. In most 
cases, it would be reasonable just to wait until the 
symptoms of the self-limiting illness subside, mean- 
while replacing fluid and electrolyte losses, but 
travellers want an immediate cure as, e.g., they may 
wish to go with their group to the next safari lodge. 
Oral rehydration therapy is the most important means 
of curing diarrhoeas in inhabitants in the third world 
and it is also indicated in small children and elderly 
patients with TD, but the oral rehydration salts 
actually marketed will in fact tend to increase the 
number of unformed bowel movements (WHO, 
1988). Various studies have shown that loperamide is 
the fastest acting agent o treat non-invasive traveller’s 
diarrhoea (Table 2), and there is no indication that 
complications may occur in such cases. This is the 
treatment of choice in mild to moderate, non-invasive 
illness, but it is contraindicated in dysentery 
(DUPONT 81 HORNICK, 1973; STEFFEN et al., 1984). 
Combination therapy with loperamide plus 
trimethoprim/sulfamethoxazole results in faster dis- 
appearance of symptoms with a mean duration of 
illness of one hour, which is difficult to improve 
Table 3. Malaria: morbidity and mortality without chemo- 
prophylaxis’ 
Destination 
Incidence rate Mortality rate 
per month Case fatality per month 
per lo6 rate (%) per lo6 
West Africa 
British 
Other European 
East Africa 
British 
Other Euronean 
6810s 2 136 
24000 2 480 
1960b 
15000 : 3:: 
“Sources: PHILLIPS-HOWARD et al. (1990), STEFFEN et al. 
bTrimethoprim+sulphamethoxazole. (1990). 
‘Oral rehydration solution. bAttack rate per journey. 
Regimen Prophylactic effectiveness (+ 95% C.I.) 
-500 -400 -300 -200 -100 0 +20 +40 +60 +80 +lOO% 
I I , I 1 I I I I I I I 
No chemoprophylaxis 0 
Chloroquine 300 mglwk 
I 4 ,----------------*---------I 
Chloroquine 600 mglwk I I 
Mefloquine q 
PYRlDapsone (Maloprlm) ~--------------------------------- *-----------------------I 
PYRlSDX (Fansidar) I i 1*-*--H 
Chloroquine + Proguanll ,-------------+----, 
I Sfeffen R. et al. Bull WHO (1990) 
I-*-*--l Steffen R. 81 al. unpublfshed data (MALPRO 11) I- 
(only >lOOO person-months of exposure) 
C------l Phlllfps-Howard P. 81 al. Brlt Med J (1990) 
Fig. 4. Prophylactic effectiveness of various regimens of malaria chemoprophylaxis in East Africa. 
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was available, it was used by about 4% of travellers to 
Africa. Mefloquine in a dosage of 750-1500 mg/24 h 
was associated with nausea and dizziness in 30-50%. 
It is not known how often use of standby medication 
was justified. 
Malaria diagnosis is often delayed. In each of the 4 
cases who died of malaria in our first cohort of 44 000 
travellers, diagnosis was late, some physicians believ- 
ing that their patients could not develop severe 
malaria under chloroquine prophylaxis (LOBEL, 1985; 
STEFFEN et al., 1990). 
(ERICSSON et al., 1990). Those 2 drugs can be 
recommended for the travel kit. Ultimately, it should 
be possible to have a single drug for self-therapy, 
or-even better--to have hotels where travellers do 
not acquire TD. 
Malaria 
Two recent studies (PHILLIPS-HOWARD et al., 
1990: STEFFEN et al.. 19901 tive an account of the 
morbidity of malaria’in traialers who have visited 
Africa without using chemoprophylaxis (Table 3), 
and both illustrate the importance of this infection. If 
there is a difference between the 2 studies, it may be 
due to differences in design. The British study was 
based on reports to the Malaria Reference Laboratory 
and, therefore, cases diagnosed abroad were not 
included and notification of cases was incomplete; in 
addition, only attack rates were presented. In our own 
surveys, the second of which is still in progress, 
cohorts of travellers recruited aboard British, German 
and Swiss charter flights returning from East Africa 
are being followed up. 
Analysis of the effectiveness of various chemo- 
prophylactic regimens-unadjusted for compliance 
and probably a better reflection of real conditions than 
the efficacy in compliant users-shows that, in East 
Africa, chloroquine 300 mg base per week failed to 
protect travellers in the 3 studies summarized in Fig. 
4. In contrast, mefloquine, and to a lesser extent 
chloroquine plus proguanil, offered fair or even good 
protection. Similar results were found in West Africa. 
Furthermore, an observational, uncontrolled study of 
Peace Corps volunteers showed that even higher 
effectiveness could be achieved with mefloquine, if 
&en at weeklv instead of bi-weeklv intervals (LOBEL 
it aE., 1991). s 
Malaria chemoprophylaxis is associated with 20- 
25% of self-remrted adverse ffects, 60% of which are 
only slight. Similar rates of medic& consultations for 
adverse vents were reported with all drugs. As shown 
in Table 4, mefloquine had a similar pattern of 
adverse events as chloroquine, except that it was 
significantly more often associated with dizziness. In 
17 000 prophylactic mefloquine users one patient 
(using continuous antiepileptic medication) was 
admitted to hospital for a seizure., which indicates the 
rarity of severe neuropsychiatnc reactions (WHO, 
1989). 
Some experts recommend that travellers should 
carry standby reserve medication for self-therapy or 
for use by the local doctor. When standby medication 
Sexually transmitted diseases (STDs) 
Casual sexual contacts abroad may play a major role 
in the transmission of human immunodeficiency virus 
(HIV) (BLAXHULT & B~TTIGER, .1989) and other 
STDs (DE SCRYVER 8~ MEHEUS, 1989). In a pilot 
study investigating the frequency and characteristics 
of casual sexual contacts of Swiss short-term visitors 
to developing countries, casual sexual contacts were 
frequently reported (Table 5). The participants in 
many of these contacts were unprotected by condoms, 
partly due to drunkenness (STRICKER et al., 1990). 
Intervention studies must determine how future 
travellers can best be influenced to protect them- 
selves. 
Table 5. Casual sexual contacts of Swiss tourists in 
tropical Africa, the Far East and Latin America, 
1987/1988O 
Group High riskb ComparisonC 
Casual sexual contacts 49182 (67%) 5066 (4%) 
Type of contacts 
Prostitutes 27/55 (49%) 
Other indigenous 26155 (47%) 
Only Europeans 2155 (4%) 
>3 partners 14/55 (25%) 
Condom use 
Men, aged 20-39 years 27134 (79%) 
Men, ased 340 years 
Women 
?3ource: STRICKER et al. (1990). 
bAttenders at vaccination centres. 
‘Random sample of airline charter passengers. 
dUse by partner. 
Table 4. Adverse events reported by travellers and attributed to malaria chemoprophylaxis (percent) 
Chloroquine 
No 
chemoprophylaxis 
30zeeT8/ 60ze,“k”’ PYIU PYR/SDX” Chloroquine 
Mefloquine Proguanil SDX” +Mefloquine +Proguanil 
it::; of subjects E 363 8.0 773 82 4478 14s 
Mouth ulcers 0 ::; 0’:; 
9243 11.2 
1.1 z:; ;:: g:; 
15.2 930 
4.3 
Headache 
Dizziness ;:; ;:; 2:; 
1.2 4.1 
Visual problems 0,2 ::; 4.3 2.0 i.4 
;:; 2.8 ::: 
1.7 
Depression 0 0.3 
Insomnia 0 5.8 ;:z 
1.2 
2.1 
A:? ;:i 
;:; 
Any adverse event 1.4 24.2 23.9 
2% 
20.7 
12 . 13.1 
28.1 
‘Pyrimethamine+sulfadoxine. 
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Immunizable diseases 
Table 6 shows that immunizable infections are far 
less a threat to travellers than malaria, and that of 
these infections the various hepatitis serotypes are the 
most important. 
Hepatitis 
Various retrospective studies (STEFFEN et al., 1977; 
SKINHBJ et al., 1981; APOTHBLOZ et al., 1982; 
IWARSON & WAHL, 1983) and one follow-up study 
(STEFFEN et al., 1987) have investigated the risk of 
im rted he 
difr 2 
atitis. The hepatitis attack rates did not 
er sigm cantly between regions, or even indi- 
vidual countries, within the developing world. Hepa- 
titis A is the most frequent serotype of hepatitis 
imported from the third world; it is responsible for 
about 60% of hepatitis cases in returning travellers. 
Henatitis B and henatitis non-A. non-B (now C and E) 
we;e each diagnosed in about 13% of the cases, while 
some 10% remained unclassified. In contrast, hepati- 
tis A played only a minor role in infections acquired 
within Europe. In the follow-up study, 8 of almost 
8000 travellers to various developing countries, the 
majority having stayed in luxury hotels, were di- 
agnosed as having symptomatic hepatitis A. Their 
mean duration of incapacity to work was 33 d. Only a 
French group has published a hepatitis A seroconver- 
sion study in unprotected volunteers working in the 
‘bush’ of Central or West Africa! of whom 19/1000 
seroconverted per month, the majority with jaundice 
(LAROUZB et al., 1987). 
The available retrospective, follow-up and serocon- 
version data suggest that the incidence rate of 
svmntomatic heoatitis A for a one-month iournev 
from an indus&ialized country to a developing 
countrv is about 3(-6)/1000 for the usual non-immune 
travel&. The risk seems to be 6 times as great in 
hikers or other persons who eat and drink under poor 
hygienic conditions. 
As recently reviewed (STEFFEN, 1990), professional 
people working in developing countries -are at high 
risk of hepatitis B. They have a monthly incidence of 
symptomatic or asymptomatic hepatitis B of 80-420/ 
100 000. with 20-60/100 000 beine svmotomatic. In 
contrast; tourists have a very low incidence, unless 
they disregard basic hygienic rules. 
Typhoid fever 
‘Several surveys have documented the attack rate of 
imported typhoid fever (STEFFEN, 1982; TAYLOR et 
al., 1983; PHLS, 1984). All showed rates of 1 in 
30 000. In India, Senegal and North Africa a ten-fold 
higher risk was found (SCHOTTENHAML, 1989). Per- 
sons travelling off the beaten track were at higher 
risk. The case fatality rate did not exceed 1%. 
Poliomveliris 
Recently, 47 cases of imported poliomyelitis in 
residents of Eurooe, Canada or the USA, who often 
had been in the third world for less than a-week, were 
reviewed (RUBLI et al., 1987). As asymptomatic 
infections are far more frequent than symptomatic 
ones, we must assume that the incidence of infection 
in unvaccinated travellers is at least 20 per 1 000 000. 
Surprisingly, only 18 contact cases in industrialized 
nations were recorded. 
dise.ases in 
C0UWk.S’ 
Table 6. 
1000000 
Infection 
Incidence Case Mortality 
rate per fatality rate per 
month rate (%) month 
Hepatitis A 3000 (-6000) 0.1 3 (-4 
Hepatitis B, expatriates 800 (-2400) 2 16 (-48) 
(symptomatic or asymptomatic) 
Typhoid 30 1 0.3 
India, N/NW Africa 300 1 3 
Poliomyelitis 
Symptomatic 
(-1OO‘k) 
20 0.2 
Asymptomatic 20 - ?iU 
contacts 
Cholera 3 2 0.06 
“No data available for diphtheria, Japanese encephalitis, measles, 
meningococcal meningitis, rabies, tetanus, tuberculosis, yellow 
fever. 
Cholera 
Cholera is rarely imported into industrialized coun- 
tries. Between 1975 and 1981 only 129 such cases 
were renorted to the World Health Organization. 
Detailed analysis showed an attack rate of 2 in 
1 000 000 (SNYDER & BLAKE, 1982; MORGER et al., 
1983). All infected patients had a short stay m 
hospital, and the case fatality rate in travellers was 
below 2%. Apparently, cases are rarely treated abroad 
and asymptomatic imported infections do not cause 
epidemics. 
Yellow fezier 
Yellow fever is the only immunization which may 
be required by health authorities in the third world 
from travellers arriving from industrialized countries. 
Only 5 cases in travellers (4 unvaccinated) have been 
published in the last 10 years, due to the fact that 
immunization is required. 
Rare immunizable diseases 
No data exist on the risk of Japanese encephalitis 
and meningococcal disease! which have only rarely 
and anecdotally been described in civilian travellers; 
the latter usually occurred in situations in which 
travellers lived in crowded conditions. It is impossible 
to guess at an incidence rate; it is probably below 1 in 
1 000 000. Just one plague case has been reported in 
an international traveller since 1966 (ANONYMOUS, 
1991). In contrast, many cases of rabies in travellers 
have been reported, but again there are insufficient 
data to estimate rates of exposure (NICHOLSOF+ 1990). 
The incidence of animal bites in expatriates hving in 
the third world is 2% (Brunner, personal communica- 
tion). Imported measles is responsible for 26% of all 
cases in the USA. Surprisingly, there are hardly any 
published data on diphtheria or tetanus in travellers. 
Conclusions concerning immunization 
Being aware of epidemiological data, various 
strategies of immunization for travellers can be 
considered. One strategy is to immunize against every 
potential risk. Some travellers may thereafter have a 
‘St Sebastian syndrome’, and feel like the Roman 
officer who was tortured with arrows which were not 
to kill him. The minimal option would be based on 
cost versus benefit considerations, but not even 
immunoglobulin prophylaxis results in a ratio which 
clearly shows that it is necessary. Thus, every 
physician will have to decide at which morbidity and 
mortality rates he wants to draw the line, above which 
he does, and below which he does not, immunize. 
Above all, he should not protect his travellers against 
rare risks, while leaving them unprotected against 
more important ones. For reasons unrelated to travel, 
Europeans should be immune against poliomyelitis, 
tetanus and diptheria, as well as against measles, 
mumps and rubella. Travellers should be encouraged 
to receive immunoglobulin and, hopefully, soon 
active combined hepatitis A and B vaccine. As long as 
the prices for the latter stay above f30 per dose, it may 
well be reserved for those working abroad. The 
indication for typhoid vaccine can be restricted to 
those eating and drinking off the beaten track (USA, 
1989; WHO, 1990). Immunization against rare infec- 
tions is reserved for travellers who are likely to be at 
unusually high risk. We must realize that if future 
travellers expect too many injections, they may avoid 
their doctors and neglect to take important prophylac- 
tic measures. 
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